SCHEMBL12204584

SCHEMBL12204584

NC(=O)C1CCN(CCS(=O)(=O)c2ccccc2)CC1

nearest known ligand 0.76

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.76
▸ GAA P10253 3/20 0.76
▸ MEN1 O00255 2/20 0.57
▸ KMT2A Q03164 2/20 0.57
▸ LTA4H P09960 1/20 0.51
▸ MAPK1 P28482 2/20 0.48
▸ HTR7 P34969 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ LMNA P02545 1/20 0.46
▸ DRD2 P14416 1/20 0.46
▸ HRH1 P35367 1/20 0.46
▸ DRD3 P35462 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ HTR2A P28223 1/20 0.45
▸ KCNH2 Q12809 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15965548 0.88 ALDH1A1 (0.60) ALDH1A1GAAMEN1KMT2ALTA4H
SCHEMBL14375268 0.80 MEN1 (0.63) ALDH1A1GAAMEN1KMT2AMAPK1
SCHEMBL5365328 0.77 ALDH1A1 (0.64) ALDH1A1GAAMEN1KMT2ALTA4H
SCHEMBL14476103 0.77 MEN1 (0.73) ALDH1A1MEN1KMT2ALTA4HMAPK1
SCHEMBL5367392 0.77 HTR2A (0.71) ALDH1A1GAALTA4HHTR2A
SCHEMBL24732017 0.76 KMT2A (0.58) ALDH1A1GAAMEN1KMT2AMAPK1
SCHEMBL5368435 0.76 CYP1A2 (0.65) ALDH1A1GAAMEN1KMT2ALTA4H
SCHEMBL13604236 0.76 KMT2A (0.71) ALDH1A1MEN1KMT2ALTA4HMAPK1
SCHEMBL20240865 0.75 ALDH1A1 (0.72) ALDH1A1GAAMEN1KMT2ANPSR1
SCHEMBL6980399 0.74 KCNA3 (0.66) KMT2ALTA4HTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9566284-B2 Agents and methods for treating ischemic and other diseases NONO INC. (CA) 2017-02-14 — — US disclosed
US-9566284-B2 Agents and methods for treating ischemic and other diseases NONO INC. (CA) 2017-02-14 — — US disclosed
US-20110251182-A1 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2011-10-13 — — US disclosed
US-20110251182-A1 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2011-10-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251182-A1 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES TRPM7, TRPM8, TRPM6 ALDH1A1 1703/4885GAA 869/4885MEN1 2102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback